Insulin-Mimetic Agents for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for bone fracture healing and spinal fusion are costly and inefficient, with existing treatments like BMPs causing side effects and requiring daily patient compliance, while existing technologies lack effective in vivo evaluation of insulin-mimetic agents for spinal fusion.
Innovation Solution
Local administration of insulin-mimetic agents such as zinc, vanadium, tungsten, molybdenum, niobium, selenium, or manganese compounds, either alone or with carriers, to stimulate insulin pathway signaling and enhance bone regeneration and spinal fusion, using drug delivery devices and surgical procedures to facilitate their application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone morphogenic proteins (BMPs) are used for bone fracture healing, then bone regeneration is enhanced, but treatment cost increases and side effects occur
Solution Approach 1:
The patent changes the molecular target from complex protein signaling (BMPs) to the insulin signaling pathway using insulin-mimetic agents. This parameter change in the therapeutic mechanism reduces side effects while maintaining bone regeneration efficacy, as the insulin pathway is more broadly activated without the specific tissue-related side effects of BMPs.
Solution Approach 2:
The patent employs small-molecule insulin-mimetic agents that can be administered locally and degraded/metabolized quickly, replacing expensive, complex protein-based BMPs. The small-molecule nature allows for cost-effective production and administration while achieving the desired bone healing effect.
2Reliability
If bone morphogenic proteins (BMPs) are used for bone fracture healing, then bone regeneration is enhanced, but treatment cost increases
Solution Approach 1:
The patent replaces expensive protein-based BMPs with cost-effective small-molecule insulin-mimetic agents. These small molecules can be synthesized at lower cost and administered through simple local delivery methods, significantly reducing the per-application treatment cost while maintaining therapeutic efficacy.
Solution Approach 2:
The patent extracts the essential bone-regenerating function from complex protein structures and identifies it as being mediated through insulin pathway activation. This extraction allows for the use of simpler, cheaper small-molecule insulin-mimetics that replicate the bone-regenerating effect without the high cost of protein production and purification.
3Ease of operation
If existing bone healing technologies are used, then bone fracture treatment is provided, but patient compliance is required daily
Solution Approach 1:
The patent applies insulin-mimetic agents locally at the fracture site during the surgical procedure, performing the therapeutic action in advance before the patient leaves the hospital. This preliminary action eliminates the need for daily postoperative patient compliance while ensuring continuous therapeutic effect during the critical healing phase.
Solution Approach 2:
The patent uses local delivery systems (such as carriers or implants) as intermediaries to deliver insulin-mimetic agents directly to the fracture site. This intermediary approach bypasses the need for daily patient administration, ensuring consistent drug delivery without requiring ongoing patient compliance.
4Device complexity
If insulin-mimetic agents are administered locally, then bone regeneration is enhanced without complex molecule delivery, but effective in vivo evaluation for spinal fusion is lacking
Solution Approach 1:
The patent performs preliminary in vivo evaluation studies in animal models before human clinical application. These preliminary studies establish the safety and efficacy of insulin-mimetic agents for spinal fusion, providing the necessary evidence base before human use while maintaining simple local delivery mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Accelerates bone healing and enhances spinal fusion by improving torsional strength and bone mineral density, reducing the need for complex molecule delivery and minimizing side effects, thus offering a cost-effective and efficient treatment option.
Implementation Method 1
Local administration of insulin-mimetic agents such as zinc, vanadium, tungsten, molybdenum, niobium, selenium, or manganese compounds, either alone or with carriers, to stimulate insulin pathway signaling and enhance bone regeneration and spinal fusion
Data Source
AI summary
Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic, agents or compositions thereof to patients in need of such treatment are also disclosed.